SOUL Published in New England Journal of Medicine

September 24, 2025

Following the recent publication in the NEJM of the outcomes from the Semaglutide Cardiovascular Outcomes Trial (SOUL). Investigators reported that the use of oral Semaglutide was associated with a significantly lower risk of major adverse cardiovascular events than a placebo, without an increase in the incidence of serious adverse events. This was among persons with type 2 diabetes and atherosclerotic cardiovascular disease, chronic kidney disease, or both.

Northern Ireland Clinical Research Network Diabetes Team were delighted to be part of a Global study with Novo Nordisk.   BHSCT was one of the sites for the study, which evaluated the hypothesis that oral Semaglutide lowers the risk of cardiovascular events in patients with type 2 diabetes at high risk for cardiovascular disease.

Primary objectives were to demonstrate that oral Semaglutide lowers the risk of major adverse cardiovascular events compared to placebo, both added to standard of care in patients with type 2 diabetes and at high risk of cardiovascular events.

NICRN would like to again thank all of our participants and both the clinical and research team for their commitment and time given during their participation in the Semaglutide Cardiovascular Outcomes Trial in Patients with Type 2 Diabetes study, in BHSCT.